Mucosal Immunology Section News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mucosal immunology section. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mucosal Immunology Section Today - Breaking & Trending Today

MATEON ANNOUNCES POSITIVE INTERIM RESULTS FROM ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
MATEON ANNOUNCES POSITIVE INTERIM RESULTS FROM ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 .
Mateon Therapeutics, Inc.January 13, 2021 GMT
AGOURA HILLS, California, Jan. 13, 2021 (GLOBE NEWSWIRE) Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, reported positive interim results from its ARTI-19 clinical trial evaluating ARTIVedaTM against COVID-19.
“These interim results suggest that ARTIVeda is a well-tolerated and effective treatment for COVID-19 that produces a faster recovery time when compared to Standard of Care alone,” said Dr. Vuong Trieu, Chairman and CEO of Mateon. ....

United States , India Ministry , United Kingdom , Andhra Pradesh , Republic Of , Agoura Hills , Sri Lanka , Saran Saund , Amit Shah , Vuong Trieu , Chhatrapati Pramila Raje , Wanjun Chen , Suhas Kshirsagar , Health Services , Government Of India Ministry Health , Rajarshi Chhatrapati Shahu Maharaj Government Medical College , Mateon Therapeutics Inc , Government Medical College , Windlas Biotech Private Limited India , Windlas Biotech Private Limited , Emergency Use Authorization , Chief Business Officer , Ayurvedic Healing , Integrative Wellness Clinic , Mucosal Immunology Section , Clinical Trials Registry India ,

MATEON ANNOUNCES POSITIVE INTERIM RESULTS FROM ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 THERAPEUTIC

MATEON ANNOUNCES POSITIVE INTERIM RESULTS FROM ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 THERAPEUTIC
Mateon Therapeutics, Inc.
ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 THERAPEUTIC
AGOURA HILLS, California, Jan. 13, 2021 (GLOBE NEWSWIRE) Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, reported positive interim results from its ARTI-19 clinical trial evaluating ARTIVeda
TM against COVID-19.
“These interim results suggest that ARTIVeda is a well-tolerated and effective treatment for COVID-19 that produces a faster recovery time when compared to Standard of Care alone,” said Dr. Vuong Trieu, Chairman and CEO of Mateon.
ARTIVeda is Mateon’s lead Ayurvedic drug against COVID-19 in India and is being developed by Mateon in partnership with Windlas Biotech Private Limited (India). ARTI-19 India is being conducted by Windlas as part of Mateon’s global effort to deploy ARTIVe ....

United States , India Ministry , United Kingdom , Andhra Pradesh , Republic Of , Agoura Hills , Sri Lanka , Saran Saund , Amit Shah , Vuong Trieu , Mateon Oncotelic , Chhatrapati Pramila Raje , Wanjun Chen , Suhas Kshirsagar , Health Services , Government Of India Ministry Health , Rajarshi Chhatrapati Shahu Maharaj Government Medical College , Mateon Therapeutics Inc , Government Medical College , Windlas Biotech Private Limited India , Mateon Therapeutics , Windlas Biotech Private Limited , Emergency Use Authorization , Chief Business Officer , Ayurvedic Healing , Integrative Wellness Clinic ,